The combination therapy of Abrine (IDO1 inhibitors) with anti-PD-1 antibody has a beneficial impact on decreasing HCC growth by upregulating CD4+ or CD8+ T cells, inhibiting Treg cells, and blocking the expression of IDO1 and PD-L1. The gene discussed is CD8A; the disease is hepatocellular carcinoma.